Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Mind Medicine ( (MNMD) ) is now available.
MindMed reported its Q3 2025 financial results and business updates, highlighting significant progress in its clinical trials and financial positioning. The company completed a public offering with net proceeds of $242.8 million and plans to advance its Phase 3 studies for MM120 in GAD and MDD, with topline data expected in 2026. Additionally, MindMed is initiating a Phase 2a study of MM402 in ASD and has published positive results from its Phase 2b GAD study in JAMA, which led to MM120 receiving Breakthrough Therapy Designation from the FDA.
The most recent analyst rating on (MNMD) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Mind Medicine stock, see the MNMD Stock Forecast page.
Spark’s Take on MNMD Stock
According to Spark, TipRanks’ AI Analyst, MNMD is a Neutral.
Mind Medicine’s stock score is primarily impacted by its weak financial performance, marked by zero revenue and substantial net losses typical of clinical-stage biotech firms. The strong liquidity position is offset by reliance on equity financing. Technical analysis shows moderate positive momentum, but valuation metrics are unattractive with a negative P/E ratio. The lack of earnings call data and corporate events leaves financial performance as the dominant factor in the overall score.
To see Spark’s full report on MNMD stock, click here.
More about Mind Medicine
Mind Medicine (MindMed) Inc. is a late-stage clinical biopharmaceutical company focused on developing novel product candidates to treat brain health disorders. The company is advancing its pipeline with products like MM120, an orally disintegrating tablet of lysergide D-tartrate for generalized anxiety disorder (GAD) and major depressive disorder (MDD), and MM402, a form of R(-)-MDMA for autism spectrum disorder (ASD).
Average Trading Volume: 1,719,118
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.13B
For an in-depth examination of MNMD stock, go to TipRanks’ Overview page.